Somatostatin Antibody [J16B12] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Usage Information

Dilution
IHC1:25-1:100 IF1:25-1:100

Application
IHC, IF

Reactivity
Human, Mouse, Rat

Source
Mouse Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
13 kDa

Datasheet & SDS

Biological Description

Specificity
Somatostatin Antibody [J16B12] detects endogenous levels of total Somatostatin protein.

Clone
J16B12

Synonym(s)
somatostatin , SMST

Background
Somatostatin is a cyclic peptide hormone that arises from tissue‑specific processing of a single preprosomatostatin precursor into predominantly 14‑ and 28‑residue active forms and is produced by hypothalamic neurons, pancreatic δ cells, and enteroendocrine D cells, where it functions as a broadly inhibitory regulator of endocrine, neural, and gastrointestinal activity through a dedicated family of G protein–coupled receptors termed SSTR1–SSTR5. The mature peptides share a central Phe‑Trp‑Lys‑Thr motif required for high‑affinity receptor binding and adopt a constrained cyclic conformation that positions this pharmacophore to engage ligand‑binding pockets formed by transmembrane domains III–VII and extracellular loop 2 of SSTRs, with SST‑14 preferentially acting in the brain and SST‑28 enriched in gastrointestinal actions. All five somatostatin receptors are seven‑transmembrane Gi/o‑coupled receptors that, upon ligand binding, inhibit adenylyl cyclase and reduce intracellular cAMP, activate phosphotyrosine phosphatases, and modulate MAP kinase cascades, while individual subtypes couple to additional effectors including inwardly rectifying K⁺ channels, voltage‑gated Ca²⁺ channels, Na⁺/H⁺ exchangers, and phospholipase C or A₂, allowing cell type–specific integration of the inhibitory signal with membrane excitability and secretory machinery. These signaling mechanisms converge on suppression of hormone and transmitter release by lowering cAMP and Ca²⁺ and by a distal effect on exocytosis, while receptor‑linked phosphatase–MAPK pathways mediate cell‑cycle control and survival, with SSTR1, 2, 4, and 5 inducing cytostatic responses via retinoblastoma protein and p21, and SSTR3 uniquely triggering p53‑ and Bax‑dependent apoptosis, giving somatostatin a direct antiproliferative and pro‑apoptotic profile in responsive tissues and tumors. As a hypothalamic hypophysiotropic hormone, somatostatin released into the portal circulation inhibits pituitary secretion of growth hormone and thyroid‑stimulating hormone, while peripheral somatostatin from pancreatic and gastrointestinal sources suppresses insulin, glucagon, gastrin, secretin, cholecystokinin, and other gut hormones, slows gastric emptying and intestinal motility, and reduces splanchnic blood flow, placing somatostatin at the center of feedback loops that coordinate nutrient intake with endocrine and digestive activity. In the nervous system, somatostatin acts as a neuromodulator co‑localized with GABA and other transmitters, influencing synaptic transmission, pain processing, and cognitive circuits through pre‑ and postsynaptic SSTRs and contributing to regulation of neuronal excitability and plasticity. Dysregulated somatostatin signaling contributes to endocrine and neoplastic disease: reduced hypothalamic somatostatin tone or impaired receptor function is associated with excess growth hormone secretion in acromegaly, while high SSTR expression on neuroendocrine tumors underlies their sensitivity to somatostatin analogs that exploit the same inhibitory pathways to control hormone hypersecretion and tumor growth, and overproduction of somatostatin in somatostatinomas leads to diabetes, steatorrhea, and gallstones through marked suppression of insulin and gastrointestinal secretions.

Background

Somatostatin is a cyclic peptide hormone that arises from tissue‑specific processing of a single preprosomatostatin precursor into predominantly 14‑ and 28‑residue active forms and is produced by hypothalamic neurons, pancreatic δ cells, and enteroendocrine D cells, where it functions as a broadly inhibitory regulator of endocrine, neural, and gastrointestinal activity through a dedicated family of G protein–coupled receptors termed SSTR1–SSTR5. The mature peptides share a central Phe‑Trp‑Lys‑Thr motif required for high‑affinity receptor binding and adopt a constrained cyclic conformation that positions this pharmacophore to engage ligand‑binding pockets formed by transmembrane domains III–VII and extracellular loop 2 of SSTRs, with SST‑14 preferentially acting in the brain and SST‑28 enriched in gastrointestinal actions. All five somatostatin receptors are seven‑transmembrane Gi/o‑coupled receptors that, upon ligand binding, inhibit adenylyl cyclase and reduce intracellular cAMP, activate phosphotyrosine phosphatases, and modulate MAP kinase cascades, while individual subtypes couple to additional effectors including inwardly rectifying K⁺ channels, voltage‑gated Ca²⁺ channels, Na⁺/H⁺ exchangers, and phospholipase C or A₂, allowing cell type–specific integration of the inhibitory signal with membrane excitability and secretory machinery. These signaling mechanisms converge on suppression of hormone and transmitter release by lowering cAMP and Ca²⁺ and by a distal effect on exocytosis, while receptor‑linked phosphatase–MAPK pathways mediate cell‑cycle control and survival, with SSTR1, 2, 4, and 5 inducing cytostatic responses via retinoblastoma protein and p21, and SSTR3 uniquely triggering p53‑ and Bax‑dependent apoptosis, giving somatostatin a direct antiproliferative and pro‑apoptotic profile in responsive tissues and tumors. As a hypothalamic hypophysiotropic hormone, somatostatin released into the portal circulation inhibits pituitary secretion of growth hormone and thyroid‑stimulating hormone, while peripheral somatostatin from pancreatic and gastrointestinal sources suppresses insulin, glucagon, gastrin, secretin, cholecystokinin, and other gut hormones, slows gastric emptying and intestinal motility, and reduces splanchnic blood flow, placing somatostatin at the center of feedback loops that coordinate nutrient intake with endocrine and digestive activity. In the nervous system, somatostatin acts as a neuromodulator co‑localized with GABA and other transmitters, influencing synaptic transmission, pain processing, and cognitive circuits through pre‑ and postsynaptic SSTRs and contributing to regulation of neuronal excitability and plasticity. Dysregulated somatostatin signaling contributes to endocrine and neoplastic disease: reduced hypothalamic somatostatin tone or impaired receptor function is associated with excess growth hormone secretion in acromegaly, while high SSTR expression on neuroendocrine tumors underlies their sensitivity to somatostatin analogs that exploit the same inhibitory pathways to control hormone hypersecretion and tumor growth, and overproduction of somatostatin in somatostatinomas leads to diabetes, steatorrhea, and gallstones through marked suppression of insulin and gastrointestinal secretions.

References
https://pubmed.ncbi.nlm.nih.gov/10433861/ https://pubmed.ncbi.nlm.nih.gov/15533778/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%